Brief: Northstrive Biosciences Announces Positive FDA Response Supporting A Submission Of IND For A Phase 2 Clinical Trial For EL-22 In Combination With GLP-1 Receptor Agonist For Obesity Treatment
24/04/2025 13:18
April 24 (Reuters) - PMGC Holdings Inc ELAB.O: NORTHSTRIVE BIOSCIENCES ANNOUNCES POSITIVE FDA RESPONSE SUPPORTING A SUBMISSION OF IND FOR A PHASE 2 CLINICAL TRIAL FOR EL-22 IN COMBINATION WITH GLP-1 RECEPTOR AGONIST FOR OBESITY TREATMENT PMGC HOLDINGS INC - NORTHSTRIVE TO FILE IND APPLICATION IN 2025 Source text: ID:nGNX63yVMb Further company coverage: ELAB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on PMGC Holdings
See all newsBrief: PMGC Announces DBA As NorthStrive Holdings Trademark License Agreement, & Website Update
U.S. STOCKS ON THE MOVE- Medtronic, Comstock, Apple
U.S. STOCKS ON THE MOVE-GoPro, TXNM Energy, Emergent BioSolutions
U.S. STOCKS ON THE MOVE-Fervo Energy, Myriad Genetics, Emergent BioSolutions
Pmgc Holdings Rises As Unit Expands Rights To Ai: discovered obesity, heart disease drug program